Local control of repeat dose rectal challenges in DNA/MVA vaccinated. macaques protected against a 1 st series of SIV challenges
|
|
- Reynard Ellis
- 5 years ago
- Views:
Transcription
1 JVI Accepts, published online ahead of print on 26 February 2014 J. Virol. doi: /jvi Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Local control of repeat dose rectal challenges in DNA/MVA vaccinated macaques protected against a 1 st series of SIV challenges 3 4 Sunil Kannanganant 1, Salaija Gangadhara 1, Lilin Lai 2, Benton Lawson 1, Pamela A Kozlowski 3, Harriet L Robinson 4, Rama Rao Amara 1,5,# 1 Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA 2 The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Emory University, Decatur, GA, USA 3 Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA 4 GeoVax, Inc., Smyrna, GA, USA 5 Department of Microbiology and Immunology, Emory University, Atlanta, GA Running title: Local control of rectal SIV challenges #To whom correspondence should be addressed: Rama Rao Amara, Phone: (404) ; FAX: (404) ; ramara@emory.edu
2 Abstract: Here we report the results of a late boost and three additional series of simian immunodeficiency virus (SIV) challenges in seven DNA/MVA vaccinated macaques who resisted a first series of rectal challenges. During 29 additional challenges delivered over 2.3 years, all animals became infected. However, 13 blips of virus in six rhesus and anamnestic Env-specific rectal IgA responses in three of the six suggested that local control of infections was occurring during the serial challenge In 2011 we reported on the prevention of infection by 12 repeated SIVE660 challenges in 5 rhesus macaques receiving a granulocyte-macrophage colony stimulating factor (GM-CSF) adjuvanted DNA/MVA vaccine and in 2 animals receiving a non-adjuvanted vaccine(6). Animals had been vaccinated with two i.m. inoculations of 3 mg of a SIV239 Gag, Pol, Env expressing DNA vaccine (D), or two inoculations of the same vaccine that co-expressed GM-CSF (Dg), followed by two i.m. boosts with 1x10 8 plaque forming units (PFU) of a SIV239 Gag, Pol, Env expressing MVA vaccine (M) in regimens designated DDMM or DgDgMM (6). The 1 st series of SIVE660 challenges was undertaken 6 months after the initial series of immunizations. Here we monitor the protected animals for one year for the presence of an occult infection, give a late MVA boost, wait 6 months and then subject the animals to a 2 nd series of 12 rectal SIVE660 challenges followed by 3 rd and 4 th series of rectal SIV251 challenges (Fig. 1A). The goals of the study were to learn more about the effects of late boosts on vaccine responses and the longevity of vaccine-mediated protection. Impressively, 6 out of the 7 animals were protected from the 2 nd series of SIVE660 challenges (Fig. 1B). The animal in the DgDgMMM group with both the lowest and a falling avidity for Env-specific Ab (Fig. 2B), was infected at the 10 th challenge (Fig. 1C). The first series of SIV251 challenges was initiated with a dose of 120 TCID 50. When the 5 unvaccinated controls were slow to become infected (one infection in 5 challenges), the challenge dose was increased to 650 TCID 50. The higher dose infected the 4 uninfected
3 45 46 controls within 4 challenges. All 6 of the vaccinated animals became infected with the last animal becoming infected at challenge Figure 2 shows the patterns of immune responses through the initial series of immunizations, the first series of challenges, the one year observation period before the late MVA boost, the third late MVA boost and six months past the late MVA boost. Consistent with macaques not becoming infected, animals that were protected during the 1 st series of challenges showed no changes in the magnitudes of their SIV-specific serum IgG or rectal IgA responses during the 1 st series of challenges or during the one year observation period prior to the late boost (Fig. 2B and 2C). The magnitudes of Ab and T cell responses expanded and contracted with MVA boosts while the quality of the Ab, as measured by avidity, tended to increase with boosts (Fig. 2). Following the late MVA boost, the magnitudes of elicited Ab, CD4 and CD8 T cell responses expanded to peak values similar to those observed in the first series of immunizations (Fig. 2 B-E). The only parameter to show a trend for a significant increase was the avidity of the Env-specific IgG response, which rose in 6 of the 7 rhesus from indices in the mid 50s post the first series of immunizations to indices in the mid 60s post the late MVA boost (p=0.06) (Fig. 2A). The contractions of the serum IgG, rectal IgA and T cell responses were overall similar following the 1 st series of immunizations and the late MVA boost. The one exception was the contraction of CD4 T cells which was less acute after the late MVA boost than after the initial series of immunizations (p=0.05) (Fig. 2D). Most of the contraction of responses occurred in the 1 st 12 weeks post immunization Throughout the 2 nd series of E660 challenges and the two series of SIV251 challenges, transient blips of RNA (<1000 copies, verified by an independent repeat assays) were detected in the 6 serially challenged animals to enter the 3 rd and 4 th series of challenges. Thirteen of the 14 blips were not associated with an anamnestic Env-specific IgG response in serum and are considered to not have established systemic
4 infections (Fig 3A and 3B). Three of the animals with blips had significant expansions of Env-specific IgA but not IgG in rectal secretions (rhesus RLe11, RWg11 and RFm11, Fig. 3C). This would be consistent with a rectally contained infection stimulating a local IgA response without stimulating a local IgG response (3). For one animal, RKk11, the final blip of SIV251 RNA was associated with an anamnestic serum IgG response, but the failure to establish viremia (Fig. 3). This animal was considered infected and represented the last animal to become infected. Post infection levels of viral RNA revealed some control of post infection viremia. These studies considered week one of infection to be the 1 st week in which viral RNA was detected in plasma (Fig. 4). The one animal infected by the 2 nd series of SIVE660 challenges had a 1000-fold lower level of peak RNA and a 100-fold lower level of viral RNA at 24 weeks post infection than the 8 unvaccinated controls. The SIV251 infected animals had fold lower levels of peak viral RNA (p=0.02, Mann-Whitney test) but no significant reduction at 24 weeks post infection compared to the unvaccinated controls (Fig. 4, C-F). By 24 weeks post infection, RKk11 who had shown a blip associated with seroconversion in the absence of detectable viremia, had become viremic (Fig 3A and 3B, Fig 4D). The serial challenges revealed the DNA/MVA vaccines plus a late MVA boost eliciting remarkably durable protective immunity for SIVE660 (Fig. 1). In addition, the vaccines markedly delayed the acquisition of SIV251 challenges. The poorer protection observed against the SIV251 challenges than the SIVE660 challenges was anticipated because SIV251 is hard to neutralize, whereas SIVE660 is a virus swarm that includes viruses that are neutralization sensitive (7) The data suggest that all six of the extensively challenged animals exhibited local control of SIVE660 infection. This is suggested by transient blips of virus that were associated in three of the six animals with anamnestic mucosal IgA but not IgG responses (Fig. 3). One of the desirable characteristics for a vaccine is the ability to establish a memory response that can undergo a protective anamnestic
5 expansion in response to an infection. Because of the ability of HIV to rapidly establish latent reservoirs and undergo immune escape, it has been proposed that an HIV vaccine will need to be a sterilizing vaccine, or a vaccine that prevents infection in the absence of an anamnestic response. To achieve sterilizing immunity, a vaccine needs to elicit persisting levels of Ab that are sufficient to block an incoming infection. Here, in a series of repeated challenges over a period of 3 1/2 years, we report findings that suggest that a simian DNA/MVA vaccine may not require sterilizing immunity to provide protection, but rather can control rectal challenges by local responses, some of which can be scored as anamnestic IgA responses in rectal secretions. The occurrence of low level blips of virus during serial challenge has also been reported for intravaginal exposures following vaccination with a gp41 virosome vaccine (1). This vaccine elicited Ab in cervical secretions that inhibited trancytosis and showed antibody-dependent cellular cytotoxicity (1). The ability of host immune responses to control local infections has also been suggested for exposed uninfected commercial sex workers and discordant couples (9, 10, 12). Analyses for immune responses in these cohorts have revealed adaptive mechanisms for protection in some individuals (2, 5, 8, 11). In the case of vaccinated people, adaptive responses elicited by the vaccine, both in the presence and absence of anamnestic expansion, could contribute to local control of infection. We suggest that this is happening in macaques for both GM-CSF-adjuvanted and non GM-CSF adjuvanted DNA/MVA SIV vaccines. Acknowledgements. We are indebted to S. Reuland and H. Drake-Perrow for expert administrative support. This work was supported by Integrated Preclinical/Clinical AIDS Vaccine Development program project 5U19 AI (HLR) and the Emory University CFAR P30 AI and by the NCRR (currently supported by the Office of Research Infrastructure Programs)/NIH base grant P51OD to the Yerkes National Primate Research Center.
6 Figure 1. Temporal immunizations, challenges and infection outcomes. A. Immunization and challenge schematic. The schematic presents the timing of vaccinations and challenges and the doses in tissue culture infectious doses 50 (TCID 50 ) of the serial rectal challenges. Age matched controls were added to the study at the time of each serial challenge. The SIVE660 challenge was the SIVsmE660 Hirsch200 stock. The SIV251 stock was the Desrosiers-2006 stock, day 9 harvest provided by DAIDS. B-D. Kaplan- Meier curves for % uninfected for the indicated serial challenge. The numbers of animals in each group are indicated in the graphs. Ch, challenge. Figure 2. Effect of a late boost on temporal immune responses in vaccinated and challenged animals. See Figure 1 and Text for detail on vaccination and challenge regimen. A. Avidity of the elicited Envspecific Ab for the 239 Env concanavilin A-captured from Triton-X-100 disrupted virus like particles produced by transient transfection (6) B. Titer of binding Ab for SIV239 gp140 (Immune Technology Corp) estimated against a standard curve of rhesus IgG (6). C. Specific activity (S.A.) for Env-specific IgA (ng of Env-specific IgA per µg of total IgA) in rectal secretions for SIV251 gp130 (Immune Diagnostics, Woburn, MA (6). D, Magnitudes of responding T cells to Gag and Env determined using intracellular cytokine staining for IFN following stimulation with pools of SIV239 peptides (15-mers overlapping by 11)(4). Vaccination groups are indicated above line graphs and the time in trial above boxplots. DgDgMMM and DDMMM indicate two DNA and three MVA immunizations. Boxplots (minimum, maximum whiskers) are in fuchsia for the DgDgMM and turquoise for the DDMM regimens. Statistics for box plots use a Paired T test and are two-sided. Pre-Ch, point taken 2 to 3 weeks pre-challenge Figure 3. Data consistent with the control of local infections during serial challenges. A. Temporal levels of viral RNA in plasma during the 2 nd through 4 th series of challenges. Levels of viral RNA were tested using a qpcr assay with a sensitivity of 40 and 80 copies per ml for SIVE660 and SIV251 respectively. All blips were confirmed in independent assays. B. Tests for post infection anamnestic
7 serum IgG responses during serial challenges (see Fig. 2). C. Number of blips in different animals during the serial challenges and specific activities of rectal IgA and IgG at the indicted times. The cut-off value for the specific activity of IgA was Fold increases in the specific activity were calculated for week 165 relative to week 137. A 3-fold increase in specific activity is considered significant. Mucosal Ab responses were measured against SIV251 gp130 as previously described (4, 6). Pre-Ch, pre-challenge Figure 4. Temporal levels of post infection viral RNA. Panels A and B present data for the 2 nd challenge with SIVE660 and panels C-F for the 4 th challenge with SIV251. A and C show data for individual unvaccinated animals, B, D and E for individual vaccinated animals and F for the geometric means of data for each group. RNA levels were determined as described in Figure 3. SIV251 viral load is not available for 3 vaccinated animals at week 24 because these animals were euthanized before that time point.
8 References 1. Bomsel, M., D. Tudor, A. S. Drillet, A. Alfsen, Y. Ganor, M. G. Roger, N. Mouz, M. Amacker, A. Chalifour, L. Diomede, G. Devillier, Z. Cong, Q. Wei, H. Gao, C. Qin, G. B. Yang, R. Zurbriggen, L. Lopalco, and S. Fleury Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity. 2. Dorrell, L., A. J. Hessell, M. Wang, H. Whittle, S. Sabally, S. Rowland-Jones, D. R. Burton, and P. W. Parren Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 14: Islam, D., B. Veress, P. K. Bardhan, A. A. Lindberg, and B. Christensson Quantitative assessment of IgG and IgA subclass producing cells in rectal mucosa during shigellosis. Journal of clinical pathology 50: Kannanganat, S., P. Nigam, V. Velu, P. L. Earl, L. Lai, L. Chennareddi, B. Lawson, R. L. Wilson, D. C. Montefiori, P. A. Kozlowski, B. Moss, H. L. Robinson, and R. R. Amara Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine. J Immunol 185: Kaul, R., F. Plummer, M. Clerici, M. Bomsel, L. Lopalco, and K. Broliden Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 15: Lai, L., S. Kwa, P. A. Kozlowski, D. C. Montefiori, G. Ferrari, W. E. Johnson, V. Hirsch, F. Villinger, L. Chennareddi, P. L. Earl, B. Moss, R. R. Amara, and H. L. Robinson Prevention of Infection by a Granulocyte-Macrophage Colony-Stimualting Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. The Journal of Infectious Diseases 204:
9 Lopker, M., J. Easlick, S. Sterrett, J. M. Decker, H. Barbian, G. Learn, B. F. Keele, J. E. Robinson, H. Li, B. H. Hahn, G. M. Shaw, and K. J. Bar Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87: Mazzoli, S., D. Trabattoni, S. Lo Caputo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, M. L. Fusi, N. Tofani, M. Biasin, M. L. Villa, F. Mazzotta, and M. Clerici HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIVseropositive individuals. Nat Med 3: Miyazawa, M., L. Lopalco, F. Mazzotta, S. Lo Caputo, F. Veas, M. Clerici, and E. S. N. S. Group The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 23: Plummer, F. A., T. B. Ball, J. Kimani, and K. R. Fowke Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol Lett 66: Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, and et al HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1: Shearer, G. M., and M. Clerici Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 17:
10
11
12
13
CD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection
JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationUnderstanding HIV. Transmitted/Founder Viruses. Brandon Keele SAIC-Frederick National Cancer Institute
Understanding HIV Transmission Utilizing Transmitted/Founder Viruses Brandon Keele SAIC-Frederick National Cancer Institute AIDS Vaccine 2011 15 September 2011 Overview Several years ago, the CHAVI sought
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationReplication of Simian Immunodeficiency Virus (SIV) in ex Vivo Lymph Nodes as a Means to Assess Susceptibility of Macaques in Vivo
Virology 275, 391 397 (2000) doi:10.1006/viro.2000.0528, available online at http://www.idealibrary.com on Replication of Simian Immunodeficiency Virus (SIV) in ex Vivo Lymph Nodes as a Means to Assess
More informationReceived 14 October 2008/Accepted 7 February 2009
JOURNAL OF VIROLOGY, May 2009, p. 4102 4111 Vol. 83, No. 9 0022-538X/09/$08.00 0 doi:10.1128/jvi.02173-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Preclinical Studies of
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationDesign and tests of an HIV vaccine
Design and tests of an HIV vaccine Andrew McMichael, Matilu Mwau and Tomas Hanke MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK Correspondence
More informationPD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques
Brief report Related Commentary, page 1611 PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques Ravi Dyavar Shetty, 1 Vijayakumar Velu,
More informationImmunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
Article Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges Morgane Bomsel, 1,2,3, * Daniela Tudor, 1,2,3 Anne-Sophie
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationSmall-Cap Research. GeoVax Labs Inc. (GOVX-OTC)
Small-Cap Research January 22, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 GeoVax Labs Inc. (GOVX-OTC) GOVX: Unique preventive and therapeutic
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationCorrelates of Vaccine-induced Immunity
Correlates of Vaccine-induced Immunity by 9/22/2010 10:42 AM Annecy Correlates 2010 Stanley A. Plotkin References: 1) Plotkin SA. 2001. Immunologic correlates of protection induced by vaccination. Ped.
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationReceived 29 August 2002/Accepted 3 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationAdjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus
ARTICLE Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus Marcin Kwissa, 1 Rama R. Amara, 1,2 Harriet L. Robinson,
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationReceived 17 March 2003/Accepted 16 July 2003
JOURNAL OF VIROLOGY, Nov. 2003, p. 11563 11577 Vol. 77, No. 21 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.21.11563 11577.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Multigene
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationDepartment of Surgery, Duke University, Durham, North Carolina; and 7 Southern Research Institute, Frederick, Maryland
MAJOR ARTICLE Highly Attenuated Rabies Virus Based Vaccine Vectors Expressing Simian-Human Immunodeficiency Virus 89.6P Env and Simian Immunodeficiency Virus mac239 Gag Are Safe in Rhesus Macaques and
More informationHIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
More informationImmunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239
Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationReceived 9 August 2004/Accepted 26 October 2004
JOURNAL OF VIROLOGY, Mar. 2005, p. 3358 3369 Vol. 79, No. 6 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.6.3358 3369.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Protection
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationReceived 18 March 2004/Accepted 23 August 2004
JOURNAL OF VIROLOGY, Jan. 2005, p. 393 400 Vol. 79, No. 1 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.1.393 400.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. CD8 T-Cell-Mediated
More informationTreatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques
SUPPORTING INFORMATION FOR: Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques Lia Vassena, 1,2 Huiyi Miao, 1 Raffaello Cimbro,
More informationTherapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques
Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques Deborah Heydenburg Fuller 1,2,3 * a, Premeela Rajakumar
More informationReceived 8 October 1997/Accepted 5 January 1998
JOURNAL OF VIROLOGY, Apr. 1998, p. 3248 3258 Vol. 72, No. 4 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vivo Replication Capacity Rather Than In Vitro Macrophage Tropism
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle
More informationX/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Apr. 2001, p. 3753 3765 Vol. 75, No. 8 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.8.3753 3765.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Route of Simian
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationReceived 4 December 2001/Accepted 29 April 2002
JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship
More informationPreclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps
Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps NIAID Workshop, May 22-23, 2018 Nancy L. Haigwood, Oregon Health & Science University Mississippi baby case brought
More informationAcute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques
Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques Kehmia Titanji, Emory University Lakshmi Chennareddi, Emory University Matam Vijay-Kumar,
More informationProgress on new vaccine strategies against chronic viral infections
Progress on new vaccine strategies against chronic viral infections Jay A. Berzofsky,, Masaki Terabe, Igor M. Belyakov J Clin Invest. 2004;114(4):450-462. https://doi.org/10.1172/jci22674. Review Among
More informationADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV(mac)251 Challenge
University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 8-2012 ADCC Develops Over Time during Persistent
More informationPredicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus
JOURNAL OF VIROLOGY, Oct. 2004, p. 11340 11351 Vol. 78, No. 20 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.20.11340 11351.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Predicting
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationA TRIMERIC HIV-1 GP140-BAFF FUSION CONSTRUCT ENHANCES MUCOSAL ANTI- TRIMERIC HIV-1 GP140 IGA IN MICE
A TRIMERIC HIV-1 GP140-BAFF FUSION CONSTRUCT ENHANCES MUCOSAL ANTI- TRIMERIC HIV-1 GP140 IGA IN MICE Jun Liu 1, Kiera Clayton 2, Yu Li 2, Matthew Haaland 2, Jordan Schwartz 2, Hampavi Sivanesan 2, Aamir
More informationFinal published version:
Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis Subhadra Nandakumar, Centers for Disease Control
More informationIs an HIV Vaccine Possible?
304 BJID 2009; 13 (August) Is an HIV Vaccine Possible? Nancy A. Wilson 1,2 and David I. Watkins 1,2 1 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; 2 Wisconsin National
More informationJOURNAL OF VIROLOGY, Mar. 1999, p Vol. 73, No. 3. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Mar. 1999, p. 1853 1859 Vol. 73, No. 3 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Acute Effects of Pathogenic Simian-Human Immunodeficiency
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationSignificant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen
JOURNAL OF VIROLOGY, June 2011, p. 5764 5772 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.00342-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Significant Protection
More informationIL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality
IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality Ana María Rodríguez, María Fernanda Pascutti., Cynthia Maeto.,
More informationDynamics of lentiviral infection in vivo in the absence of adaptive immune responses
Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses Elissa J. Schwartz Associate Professor School of Biological Sciences Department of Mathematics & Statistics Washington
More informationNIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2010 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Nat Med. 2010 March ; 16(3): 319 323. doi:10.1038/nm.2089. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses
More informationJOURNAL OF VIROLOGY, Oct. 1999, p Vol. 73, No. 10. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Oct. 1999, p. 8201 8215 Vol. 73, No. 10 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Role of Immune Responses against the Envelope
More informationZheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
More informationDNA/MVA Vaccines for HIV/AIDS
DNA/MVA Vaccines for HIV/AIDS Smita S. Iyer, Emory University Rama Amara, Emory University Journal Title: Vaccines Volume: Volume 2, Number 1 Publisher: MDPI 2014-02-28, Pages 160-178 Type of Work: Article
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationHIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationGM-CSF Increases Mucosal and Systemic Immunogenicity of an H1N1 Influenza DNA Vaccine Administered into the Epidermis of Non-Human Primates
GM-CSF Increases Mucosal and Systemic Immunogenicity of an H1N1 Influenza DNA Vaccine Administered into the Epidermis of Non-Human Primates Peter T. Loudon 1., Eric J. Yager 2., Debbie T. Lynch 1, Amithi
More informationNew Insights on Mechanisms of Foamy Macrophage (FM) Induction and Persistence
New Insights on Mechanisms of Foamy Macrophage (FM) Induction and Persistence Marian Laderoute, Ph.D. Medical Sciences -Immunology Lab Director Immune System Management Clinic & Lab 80 Aberdeen Street,
More informationVIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer
VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of
More informationAIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationHeterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationSupporting Information
Supporting Information Walker et al. 1.173/pnas.111753118 - JR-CSF 1 3 1 4 1 5 1 6 1 7 1 8 blank beads protein A beads JR-FL - 1 3 1 4 1 5 1 6 1 7 1 8 - MGRM-C26 1 3 1 4 1 5 1 6 1 7 1 8 reciprocal serum
More informationPotent Neutralizing Serum Immunoglobulin A (IgA) in Human Immunodeficiency Virus Type 2-Exposed IgG-Seronegative Individuals
JOURNAL OF VIROLOGY, July 2004, p. 7016 7022 Vol. 78, No. 13 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.13.7016 7022.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Potent Neutralizing
More informationFeb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center
Gene Therapy Sam K.P. Kung Immunology Rm 417 Apotex Center Objectives: The concept of gene therapy, and an introduction of some of the currently used gene therapy vector Undesirable immune responses to
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationNature Medicine: doi: /nm.2109
HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael
More informationSupplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins
Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji
More informationSupplementary Figure 1.
Supplementary Figure 1. Female Pro-ins2 -/- mice at 5-6 weeks of age were either inoculated i.p. with a single dose of CVB4 (1x10 5 PFU/mouse) or PBS and treated with αgalcer or control vehicle. On day
More informationA PROJECT ON HIV INTRODUCED BY. Abdul Wahab Ali Gabeen Mahmoud Kamal Singer
A PROJECT ON HIV INTRODUCED BY Abdul Wahab Ali Gabeen Mahmoud Kamal Singer Introduction: Three groups of nations have been identified in which the epidemiology of HIV(Human Immunodeficiency Virus) varies:
More informationPRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
More informationReceived 22 July 2002/Accepted 30 September 2002
JOURNAL OF VIROLOGY, Jan. 2003, p. 179 190 Vol. 77, No. 1 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.1.179 190.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Immunization of
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationJOURNAL OF VIROLOGY, Sept. 1999, p Vol. 73, No. 9. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Sept. 1999, p. 7430 7440 Vol. 73, No. 9 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Factors Associated with Slow Disease Progression
More informationSmall-Cap Research. GeoVax Labs Inc. (GOVX-OTC) GOVX: On track to advance Ebola & HIV Programs UPDATE SUMMARY DATA ZACKS ESTIMATES
Small-Cap Research August 12, 2015 Grant Zeng, CFA Nisha Hirani, MD 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 GeoVax Labs Inc. (GOVX-OTC) GOVX: On track to advance
More informationDNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
More informationMother-to-Infant Transmission of Simian Immunodeficiency Virus Is Rare in Sooty Mangabeys and Is Associated with Low Viremia
JOURNAL OF VIROLOGY, June 2011, p. 5757 5763 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.02690-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Mother-to-Infant Transmission
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationReplicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.
Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.6P Frédéric Tangy Viral Genomics and Vaccination Laboratory Measles
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationImmunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group
report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV
More informationA Noninfectious Simian/Human Immunodeficiency Virus DNA Vaccine That Protects Macaques against AIDS
JOURNAL OF VIROLOGY, Mar. 2005, p. 3419 3428 Vol. 79, No. 6 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.6.3419 3428.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. A Noninfectious
More informationRecombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope
JOURNAL OF VIROLOGY, Apr. 2002, p. 3329 3337 Vol. 76, No. 7 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.7.3329 3337.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Recombinant
More information